During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
Hosted on MSN1mon
RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancerA new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback